TransCode Therapeutics

RNAZ

Market cap $8.2M

TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous injection TTX-MC138 demonstrated suppression of miR-10b target and extended survival in aggressive glioblastoma models Study supports future clinical development of TTX-MC138 for patients with glioblastoma BOSTON, Jan. 6, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancer, today announced the publication of preclinical research supporting the application of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme (GBM). The article was published in the peer-reviewed Journal of Functional Biomaterials (Volume 17, Issue 1).

BOSTON , Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors.

BOSTON , Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's lead therapeutic candidate TTX-MC138 as part of the Quantum Leap PRE-I-SPY clinical trial platform. The PRE-I-SPY program will incorporate TTX-MC138 in a Phase 2a dose-expansion clinical trial enrolling up to 45 patients with colorectal cancer who have completed standard curative-intent therapy and are ctDNA positive.

Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON , Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer.

Safety primary endpoint achieved Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial RECIST data with apparent stable disease lasting over 4 months in 44% of patients (7 out of 16) Safety and durability profile consistent with known mechanism of action Early signals support advancement to a Phase 2a clinical trial with established treatment dose BOSTON , Oct. 14, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announces completion of Phase 1a clinical trial with TTX-MC138, an investigational inhibitor of microRNA-10b, or miR-10b. By meeting its primary safety endpoint and defining a recommended Phase 2 dose, TTX-MC138 is moving forward into the next stage of clinical evaluation to assess its efficacy across selected metastatic diseases and for multiple indications.

RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncology Dr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which developed and commercialized the first FDA-approved RNAi drug BOSTON , May 28, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical-stage oncology company developing RNA-targeted therapeutics for the treatment of cancer, today announced the appointment of Phillip D. Zamore, Ph.D.

15 patients treated across four escalating dose levels of TTX-MC138 No significant safety or dose limiting toxicities reported 10 patients remain on study with no evidence of disease progression PD analysis at 24 hours post-dosing provides evidence of miR-10b target engagement BOSTON , May 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the third patient in Cohort 4 of its Phase 1a clinical trial has received their initial dose of TTX-MC138. All cohorts have enrolled at least three patients who have been dosed with TTX-MC138 at least once.

BOSTON , May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved an effective time at 12:01 a.m. Eastern Standard Time May 15, 2025, for its 1-for-28 reverse stock split.

Split designed to achieve compliance with Nasdaq minimum bid price requirements BOSTON , May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-28 reverse stock split. The reverse stock split was approved by TransCode's stockholders on May 2, 2025, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

A total of 13 patients treated with four escalating doses of TTX-MC138 No significant safety or dose limiting toxicities reported Two patients have so far maintained stable disease on treatment for at least seven months PD analysis at 24 hours post-dosing provides evidence of miR-10b target engagement BOSTON , May 1, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced further progress in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or miR-10b, a microRNA widely believed to be critical to the emergence and progression of many metastatic cancers.